Published in Cancer Weekly, June 1st, 1998
In both studies, ONYX-015 was found to be safe and well-tolerated, as well as biologically active in the pancreatic study. Based on these results, Onyx is planning to initiate further studies in both cancer types using novel routes of administration and regimens, including combining ONYX-015 with standard chemotherapy.
Results of the two studies were presented at the American Society of Clinical Oncology (ASCO)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.